Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steffen Pfeuffer

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 12, 2018
Sarcoidosis following alemtuzumab treatment: Autoimmunity mediated by T cells and interferon-γSteffen Pfeuffer
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 22, 2024
Psoriasisform dermatitis following anti-CD20 therapies: Immunologic lessons and management dilemmasSteffen Pfeuffer
Neurological Research and Practice|April 20, 2025
Should we stay or should we go? Recent insights on drug discontinuation in multiple sclerosisAnne Mrochen, Sven G Meuth, Steffen Pfeuffer
Expert Review of Neurotherapeutics|April 9, 2016
Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015Steffen Pfeuffer, Tobias Ruck, Christoph Kleinschnitz, et al.
Journal of Neurology|January 9, 2022
Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agentsMelanie Korsen, Steffen Pfeuffer, Leoni Rolfes, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|February 3, 2026
Delayed recovery following myasthenic exacerbation and subsequent endplate-protecting treatmentAnna Mück, Sonja Genau, Julia Emde, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 17, 2016
Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosisMark Obermann, Tobias Ruck, Steffen Pfeuffer, et al.
Journal of Visualized Experiments : Jove|March 26, 2019
Isolation of Primary Murine Skeletal Muscle Microvascular Endothelial CellsThomas Müntefering, Alexander P E Michels, Steffen Pfeuffer, et al.
Neurological Research and Practice|December 16, 2020
Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment responseLaura Bierhansl, Tobias Ruck, Steffen Pfeuffer, et al.
Neurology|October 30, 2016
Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMSSteffen Pfeuffer, Carolin Beuker, Tobias Ruck, et al.
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 12, 2018
Sarcoidosis following alemtuzumab treatment: Autoimmunity mediated by T cells and interferon-γSteffen Pfeuffer
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 22, 2024
Psoriasisform dermatitis following anti-CD20 therapies: Immunologic lessons and management dilemmasSteffen Pfeuffer
Neurological Research and Practice|April 20, 2025
Should we stay or should we go? Recent insights on drug discontinuation in multiple sclerosisAnne Mrochen, Sven G Meuth, Steffen Pfeuffer
Expert Review of Neurotherapeutics|April 9, 2016
Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015Steffen Pfeuffer, Tobias Ruck, Christoph Kleinschnitz, et al.
Journal of Neurology|January 9, 2022
Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agentsMelanie Korsen, Steffen Pfeuffer, Leoni Rolfes, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|February 3, 2026
Delayed recovery following myasthenic exacerbation and subsequent endplate-protecting treatmentAnna Mück, Sonja Genau, Julia Emde, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 17, 2016
Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosisMark Obermann, Tobias Ruck, Steffen Pfeuffer, et al.
Journal of Visualized Experiments : Jove|March 26, 2019
Isolation of Primary Murine Skeletal Muscle Microvascular Endothelial CellsThomas Müntefering, Alexander P E Michels, Steffen Pfeuffer, et al.
Neurological Research and Practice|December 16, 2020
Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment responseLaura Bierhansl, Tobias Ruck, Steffen Pfeuffer, et al.
Neurology|October 30, 2016
Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMSSteffen Pfeuffer, Carolin Beuker, Tobias Ruck, et al.
Pageof 7